A DOUBLE-BLIND, RANDOMIZED, MULTI-CENTER, PLACEBO-CONTROLLED,

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究是研究胰腺外分泌功能不全[PEI]由于囊性纤维化。PEI是一种胰腺产生厚粘液的疾病，这种粘液不允许足够的消化酶到达肠道并帮助分解食物。 虽然FDA已经批准了使用胰腺酶治疗成人PEI的适应症，但现在要求所有用于治疗儿童PEI的酶都必须确定安全性和有效性。 这项研究正在研究一种名为胰蛋白酶延迟释放胶囊的药物的安全性和有效性，用于治疗与囊性纤维化相关的胰腺外分泌不足。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research is studying pancreatic exocrine insufficiency [PEI] due to cystic fibrosis. PEI is a condition where the pancreas produces a thick mucous that does not allow enough digestive enzymes to reach the intestines and help break down food. Although the FDA has approved indications for the use of pancreatic enzymes to treat PEI in adults, it now requires that all enzymes used to treat PEI in children be established for safety and efficacy. The study is looking at the safety and effectiveness of a drug called Pancrealipase Delayed Release Capsules, for treatment of pancreatic exocrine insufficiency associated with cystic fibrosis.